RESUMO
BACKGROUND: The most common methods for measuring mobility in older adulthood include performance-based tests, such as the Timed-Up-and-Go and gait speed. While these measures have strong predictive validity for adverse outcomes, they are limited to assessing what older adults do in standardized settings, rather than what they do in their daily life. Life-space mobility, which is the ability to move within environments that expand from one's home to the greater community, has been proposed as a more comprehensive measure of mobility. The aim of this study was to determine the association between modifiable factors and life-space mobility in older adults enrolled in the Canadian Longitudinal Study on Aging (CLSA). METHODS: Life-space mobility was measured using the Life Space Index (LSI). Explanatory factors included physical, psychosocial and cognitive determinants, as well as pain, fatigue, driving status, nutrition, body mass index, smoking status, and vision. To estimate the association between the LSI and explanatory variables, univariate and multivariable ordinary least squares regression analyses were performed. RESULTS: All adults 65 years and older (n = 12,646) were included in the analysis. Fifty percent were women and the mean age was 73.0 (SD5.7). The mean LSI score was 80.5, indicating that, on average, the sample was able to move outside of their neighborhood independently. All explanatory variables were significantly associated with the LSI except for balance and memory. The top 3 variables that explained the most variation in the LSI were driving, social support and walking speed. CONCLUSION: To our knowledge, this was the first study to examine the association between life-space mobility and a comprehensive set of modifiable factors that were selected based on a theoretical framework and existing research evidence. This study had two important messages. First, driving, social support and walking speed emerged as the most significant correlates of life-space mobility in older adults. Second, life-space mobility is multifactorial and interventions that are pragmatic in their design and testing are needed that consider the complexity involved. A multi-disciplinary approach to examining life-space mobility in older adults is needed to optimize opportunities for healthy aging and develop strategies that support mobility in older adulthood.
Assuntos
Atividades Cotidianas , Envelhecimento/fisiologia , Avaliação Geriátrica/métodos , Vida Independente , Adulto , Idoso , Canadá/epidemiologia , Feminino , Humanos , Estudos Longitudinais , Limitação da MobilidadeRESUMO
BACKGROUND.: Research about occupational therapy practice in the community with people who have been imprisoned remains limited and may be considered an emerging area of practice. PURPOSE.: This paper provides a critical, first-person account about emerging occupational therapy practice with men transitioning to the community post-imprisonment. The practice context is described and reflected on from the lens of a new graduate. METHODS.: Autoethnography draws meaning from reciprocal interactions between an individual and a culture. Data was collected by the primary author through reflective journal entries and process notes pertaining to a Photovoice project. Iterative application of established evaluative criteria served as a framework in an analytical writing process. FINDINGS.: Autethnography promoted self-reflection and professional development while Photovoice provided an evidence-based framework in an emerging setting. IMPLICATIONS.: Current occupational therapy theories and models have limited applicability to inform practice with marginalized populations potentially benefitting from participatory research (e.g., Photovoice) and autoethnography.
Assuntos
Terapia Ocupacional/organização & administração , Terapia Ocupacional/psicologia , Prisioneiros , Papel Profissional/psicologia , Identificação Social , Antropologia Cultural , Humanos , FotografaçãoRESUMO
Indomethacin, a nonselective cyclooxygenase (COX) inhibitor, was modified in three distinct regions in an attempt both to increase cyclooxygenase-2 (COX-2) selectivity and to enhance drug safety by covalent attachment of an organic nitrate moiety as a nitric oxide donor. A human whole-blood COX assay shows the modifications on the 3-acetic acid part of the indomethacin yielding an amide-nitrate derivative 32 and a sulfonamide-nitrate derivative 61 conferred COX-2 selectivity. Along with their respective des-nitrate analogs, for example, 31 and 62, the nitrates 32 and 61 were effective antiinflammatory agents in the rat air-pouch model. After oral dosing, though, only 32 increased nitrate and nitrite levels in rat plasma, indicating that its nitrate tether served as a nitric oxide donor in vivo. In a rat gastric injury model, examples 31 and 32 both show a 98% reduction in gastric lesion score compared to that of indomethacin. In addition, the nitrated derivative 32 inducing 85% fewer gastric lesions when coadministered with aspirin as compared to the combination of aspirin and valdecoxib.
Assuntos
Inibidores de Ciclo-Oxigenase 2/síntese química , Indometacina/análogos & derivados , Indometacina/síntese química , Doadores de Óxido Nítrico/síntese química , Animais , Aspirina/efeitos adversos , Celecoxib , Inibidores de Ciclo-Oxigenase 2/efeitos adversos , Inibidores de Ciclo-Oxigenase 2/farmacologia , Desenho de Fármacos , Sinergismo Farmacológico , Feminino , Mucosa Gástrica/patologia , Humanos , Ácidos Hidroxâmicos/efeitos adversos , Ácidos Hidroxâmicos/síntese química , Ácidos Hidroxâmicos/farmacologia , Indometacina/efeitos adversos , Indometacina/farmacologia , Masculino , Doadores de Óxido Nítrico/efeitos adversos , Doadores de Óxido Nítrico/farmacologia , Pirazóis/farmacologia , Ratos , Ratos Sprague-Dawley , Úlcera Gástrica/induzido quimicamente , Úlcera Gástrica/patologia , Relação Estrutura-Atividade , Sulfonamidas/farmacologiaRESUMO
In mammalian cells, eicosanoid biosynthesis is usually initiated by the activation of phospholipase A2 and the release of arachidonic acid (AA) from membrane phospholipids. The AA is subsequently transformed by cyclooxygenase (COX) and lipoxygenase (LO) pathways to prostaglandins, thromboxane and leukotrienes collectively termed eicosanoids. Eicosanoid production is considerably increased during inflammation. Both COX and LO pathways are of particular clinical relevance. The COX pathway is the major target for non-steroidal anti-inflammatory drugs (NSAIDs), the most popular medications used to treat pain, fever and inflammation. Although their anti-inflammatory effects are well known, their long-term use is associated with gastrointestinal (GI) complications such as ulceration. In 1991, it was discovered that COX exists in two distinct isozymes, COX-1 and COX-2, of which COX-2 is primarily expressed at sites of inflammation and produces pro-inflammatory eicosanoids. For this reason, COX-2 selective inhibitors (COXIBs) have been developed recently as anti-inflammatory agents to minimize the risk of GI toxicity. Recently, some COX-2 selective inhibitors have shown adverse cardiovascular side effects, resulting in the withdrawal of rofecoxib and valdecoxib from the market. Selective inhibition of COX-2 without reducing COX-1-mediated thromboxane production could alter the balance between prostacyclin and thromboxane and promote a prothrombotic state, thereby explaining the observed COX-2 cardiovascular risk. In this review, we describe mechanisms for the production of pro-inflammatory eicosanoid mediators contributing to inflammation and summarize promising options for the prevention of inflammatory mediator formation and the therapeutic inhibition of pain and inflammation.
Assuntos
Anti-Inflamatórios/farmacologia , Inibidores de Ciclo-Oxigenase 2/farmacologia , Eicosanoides/biossíntese , Inflamação/metabolismo , Anti-Inflamatórios/química , Anti-Inflamatórios/uso terapêutico , Inibidores de Ciclo-Oxigenase 2/química , Inibidores de Ciclo-Oxigenase 2/uso terapêutico , Humanos , Inflamação/tratamento farmacológico , Lipoxigenase/metabolismo , Prostaglandina-Endoperóxido Sintases/metabolismoRESUMO
A series of glycolamide naproxen prodrugs containing a nitrate group as a nitric oxide (NO) donor moiety has been synthesized. These compounds were evaluated for their anti-inflammatory activity, naproxen release, and gastric tolerance. Compounds 4a, 4b, 5a, 5b, 7b, and 7c exhibited anti-inflammatory activity equivalent to that of the parent NSAID, naproxen-Na, in the rat carrageenan paw edema model. At equimolar doses relative to naproxen-Na, the NO-donor glycolamide derivatives 4a, 4b, 5a, 5b, 7b, and 7c were gastro-sparing in the rat. Naproxen formation from these NO-donor glycolamides varied among the structures examined, with the N-substituent on the amide group having a particular influence, and demonstrated their prodrug nature. Compound 7b was selected for exemplary demonstration that the glycolamide nitrates can be bioactivated to release NO. These data open the possibility that naproxen glycolamide nitrates may represent a safer alternative to naproxen as anti-inflammatory medicines.
Assuntos
Anti-Inflamatórios/síntese química , Anti-Inflamatórios/farmacologia , Naproxeno/farmacologia , Doadores de Óxido Nítrico/farmacologia , Pró-Fármacos , Amidas/química , Animais , Anti-Inflamatórios/química , Gastrite/induzido quimicamente , Humanos , Espectroscopia de Ressonância Magnética , Masculino , Espectrometria de Massas , Naproxeno/síntese química , Naproxeno/química , Doadores de Óxido Nítrico/síntese química , Doadores de Óxido Nítrico/química , Ratos , Ratos Sprague-DawleyRESUMO
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used to treat inflammation and to provide pain relief but suffer from a major liability concerning their propensity to cause gastric damage. As nitric oxide (NO) is known to be gastro-protective we have synthesized a NO-donating prodrug of naproxen named NMI-1182. We evaluated two cyclo-oxygenase (COX)-inhibiting nitric oxide donors (CINODs), NMI-1182 and AZD3582, for their ability to be gastro-protective compared to naproxen and for their anti-inflammatory activity. NMI-1182 and AZD3582 were found to produce similar inhibition of COX activity to that produced by naproxen. Both NMI-1182 and AZD3582 produced significantly less gastric lesions after oral administration than naproxen. All three compounds effectively inhibited paw swelling in the rat carrageenan paw edema model. In the carrageenan air pouch model all three compounds significantly reduced PGE2 levels in the pouch exudate but only NMI-1182 and naproxen inhibited leukocyte influx. These data demonstrate that NMI-1182 has comparable anti-inflammatory activity to naproxen but with a much reduced likelihood to cause gastric damage.
Assuntos
Inibidores de Ciclo-Oxigenase/farmacologia , Naftalenos/farmacologia , Doadores de Óxido Nítrico/farmacologia , Substâncias Protetoras/farmacologia , Animais , Anti-Inflamatórios/sangue , Anti-Inflamatórios/química , Anti-Inflamatórios/farmacologia , Aorta Abdominal/efeitos dos fármacos , Aorta Abdominal/fisiologia , Carragenina , Ciclo-Oxigenase 1/sangue , Ciclo-Oxigenase 2/sangue , Inibidores de Ciclo-Oxigenase/sangue , Inibidores de Ciclo-Oxigenase/química , Dinoprostona/antagonistas & inibidores , Dinoprostona/metabolismo , Relação Dose-Resposta a Droga , Edema/induzido quimicamente , Edema/prevenção & controle , Mucosa Gástrica/efeitos dos fármacos , Mucosa Gástrica/metabolismo , Mucosa Gástrica/patologia , Humanos , Técnicas In Vitro , Inflamação/induzido quimicamente , Inflamação/prevenção & controle , Masculino , Estrutura Molecular , Naftalenos/sangue , Naftalenos/química , Naproxeno/sangue , Naproxeno/química , Naproxeno/farmacologia , Infiltração de Neutrófilos/efeitos dos fármacos , Doadores de Óxido Nítrico/sangue , Doadores de Óxido Nítrico/química , Substâncias Protetoras/química , Ratos , Ratos Sprague-Dawley , Vasodilatação/efeitos dos fármacosRESUMO
Cyclooxygenase (COX, EC 1.14.99.1) inhibitor-nitric oxide (NO) donor (CINOD) hybrid compounds represent an attractive alternative to NSAID and coxib therapy. This report compares two CINODs, NMI-1182 (naproxen-glyceryl dinitrate) and AZD3582 (naproxen-n-butyl nitrate), for their ability to inhibit COX-1 and -2, deliver bioavailable nitric oxide, and release naproxen, using in vitro biochemical and pharmacological methods. In human whole blood, both CINODs showed inhibition, comparable to naproxen, of both COX isozymes and slowly released naproxen. Both CINODs donated bioavailable NO, as detected by cGMP induction in the pig kidney transformed cell line, LLC-PK1, but NMI-1182 was more potent by 30-100 times than AZD3582, GTN, GDN, and ISDN and considerably faster in inducing cGMP synthesis than AZD3582. The nitrate groups of GTN, NMI-1182, and AZD3582 appeared to be bioactivated via a common pathway, since each compound desensitized LLC-PK1 cells to subsequent challenge with the other compounds. Similar cGMP induction also occurred in normal, untransformed cells (human renal proximal tubule epithelial cells and hepatocytes from man, rat, and monkey); again, NMI-1182 was superior to AZD3582. NMI-1182 was also the more metabolically labile compound, releasing more absolute nitrate and nitrite (total NO(x)) in human stomach (in which NO is salutary) and liver S9 homogenates. Naproxen was also more rapidly freed from NMI-1182 than AZD3582 in human stomach, although liver S9 hydrolyzed both CINODs with similar rates. These in vitro tests revealed that NMI-1182 may be a better CINOD than AZD3582 because of its superior NO donating and naproxen liberating properties.
Assuntos
Inibidores de Ciclo-Oxigenase/farmacologia , Naftalenos/farmacologia , Doadores de Óxido Nítrico/farmacologia , GMP Cíclico/biossíntese , Ciclo-Oxigenase 1/efeitos dos fármacos , Ciclo-Oxigenase 2/efeitos dos fármacos , Humanos , Fígado/metabolismo , Naftalenos/farmacocinética , Naproxeno/farmacologia , Óxido Nítrico/biossínteseRESUMO
Incorporation of a spacer group between the central scaffold and the aryl ring resulted in a new cyclooxygenase-2 (COX-2) selective inhibitor core structure, 3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)(2-pyridyl) phenyl ketone (20), with COX-2 IC50 = 0.25 microM and COX-1 IC50 = 14 microM (human whole blood assay). Compound 20 was orally active in the rat air pouch model of inflammation, inhibiting white blood cell infiltration and COX-2-derived PG production. Our data support the identification of a novel COX-2 selective inhibitor core structure exemplified by 20.
Assuntos
Inibidores de Ciclo-Oxigenase/síntese química , Prostaglandina-Endoperóxido Sintases/metabolismo , Piridinas/síntese química , Sulfonas/síntese química , Administração Oral , Animais , Carragenina , Ciclo-Oxigenase 2 , Inibidores de Ciclo-Oxigenase 2 , Inibidores de Ciclo-Oxigenase/química , Inibidores de Ciclo-Oxigenase/farmacologia , Dinoprostona/antagonistas & inibidores , Dinoprostona/biossíntese , Inflamação/induzido quimicamente , Inflamação/metabolismo , Masculino , Piridinas/química , Piridinas/farmacologia , Ratos , Ratos Sprague-Dawley , Sulfonas/química , Sulfonas/farmacologiaRESUMO
A series of 3-(2-methoxytetrahydrofuran-2-yl)pyrazoles (4-10) was synthesized. The compounds were evaluated for their ability to inhibit cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) activity in human whole blood (HWB). The compound, 5-(4-methanesulfonylphenyl)-3-(2-methoxytetrahydrofuran-2-yl)-1-p-tolyl-1H-pyrazole 5 showed potent and selective COX-2 inhibition (IC50 for COX-1: >100 microM and COX-2: 1.2 microM).
Assuntos
Inibidores de Ciclo-Oxigenase/farmacologia , Prostaglandina-Endoperóxido Sintases/efeitos dos fármacos , Pirazóis/farmacologia , Ciclo-Oxigenase 1 , Ciclo-Oxigenase 2 , Inibidores de Ciclo-Oxigenase 2 , Inibidores de Ciclo-Oxigenase/síntese química , Inibidores de Ciclo-Oxigenase/química , Avaliação Pré-Clínica de Medicamentos , Humanos , Isoenzimas/antagonistas & inibidores , Proteínas de Membrana , Estrutura Molecular , Prostaglandina-Endoperóxido Sintases/sangue , Pirazóis/síntese química , Pirazóis/química , Relação Estrutura-AtividadeRESUMO
The synthesis of a series of novel pyrazoles containing a nitrate (ONO(2)) moiety as a nitric oxide (NO)-donor functionality is reported. Their COX-1 and COX-2 inhibitory activities in human whole blood are profiled. Our data demonstrate that pyrazole ring substituents play an important role in COX-2 selective inhibition, such that a cycloalkyl pyrazole (6b) was found to be a potent and selective COX-2 inhibitor. Other modifications at the 3 position of the central pyrazole ring (17b, 23b, 26b-I) enhanced COX-2 inhibitory potency. Among the pyrazoles synthesized, the oxime (23b) was identified as the most potent COX-2 selective inhibitor. Accordingly, 23b was profiled pharmacologically in the rat after oral administration and shown to possess potent antiinflammatory activity in the carrageenan-induced air-pouch model and less gastric toxicity than a standard COX-2 inhibitor when administered with background aspirin treatment. We suggest that the enhanced gastric tolerance of an NO-donor COX-2 selective inhibitor has the potential to augment the clinical profile of this drug class.
Assuntos
Inibidores de Ciclo-Oxigenase/síntese química , Isoenzimas/antagonistas & inibidores , Nitratos/síntese química , Doadores de Óxido Nítrico/síntese química , Pirazóis/síntese química , Administração Oral , Animais , Ciclo-Oxigenase 1 , Ciclo-Oxigenase 2 , Inibidores de Ciclo-Oxigenase 2 , Inibidores de Ciclo-Oxigenase/efeitos adversos , Inibidores de Ciclo-Oxigenase/farmacologia , Feminino , Gastrite/induzido quimicamente , Humanos , Técnicas In Vitro , Masculino , Proteínas de Membrana , Nitratos/química , Nitratos/farmacologia , Doadores de Óxido Nítrico/química , Doadores de Óxido Nítrico/farmacologia , Prostaglandina-Endoperóxido Sintases , Pirazóis/química , Pirazóis/farmacologia , Ratos , Ratos Sprague-Dawley , Relação Estrutura-AtividadeRESUMO
The combination of a nitric oxide (NO) donor and a paclitaxel-NO donor conjugate coated on a vascular stent was tested in a rabbit iliac artery model of stenosis as a potential therapy for restenosis. Paclitaxel was conjugated with a NO donor at the 7-position to give compound 7. An adamantane-based NO donor 14 was synthesized and combined with 7 to provide a burst of NO in the first few critical hours following injury to the vessel wall. Both 7 and 14 demonstrated antiproliferative activity (IC(50) = 20 nM and 15 microM, respectively) and antiplatelet activity (IC(50) = 10 and 1 microM, respectively). Stents were coated with a layer of a polymer containing test compounds. The total amount of NO eluted from the stents after a 6 h implantation in the rabbit iliac artery was 35%, 95%, and 69% of the original content for the stents coated with 7, 14, and the combination of 7 and 14, respectively. The antistenotic activity of 7 and 14 was determined in a 28-day rabbit model with two control groups (uncoated stents and polymer-coated stents) and two study groups (paclitaxel-coated stents and stents coated with the combination of 7 and 14). Polymer-coated stents caused inflammation and increased stenosis by 39% when compared to the uncoated stents. The stents coated with 7 plus 14 were as good as the uncoated stents, 41% better than the polymer-coated stents and 34% better than the paclitaxel-coated stents. These data indicate a beneficial effect of adding NO to an antiproliferative agent (paclitaxel) and suggest a potential therapeutic combination for the treatment of stenotic vessel disease.
Assuntos
Adamantano/síntese química , Antineoplásicos/síntese química , Doadores de Óxido Nítrico/síntese química , Óxido Nítrico/metabolismo , Compostos Nitrosos/síntese química , Paclitaxel/síntese química , Inibidores da Agregação Plaquetária/síntese química , Stents , Doenças Vasculares/tratamento farmacológico , Adamantano/análogos & derivados , Adamantano/química , Adamantano/farmacologia , Animais , Antineoplásicos/química , Antineoplásicos/farmacologia , Constrição Patológica/tratamento farmacológico , Artéria Ilíaca/efeitos dos fármacos , Artéria Ilíaca/patologia , Técnicas In Vitro , Músculo Liso Vascular/citologia , Músculo Liso Vascular/efeitos dos fármacos , Doadores de Óxido Nítrico/química , Doadores de Óxido Nítrico/farmacologia , Compostos Nitrosos/química , Compostos Nitrosos/farmacologia , Paclitaxel/análogos & derivados , Paclitaxel/química , Paclitaxel/farmacologia , Inibidores da Agregação Plaquetária/química , Inibidores da Agregação Plaquetária/farmacologia , Coelhos , RecidivaRESUMO
Novel series of pyrazolo[5,1-b]1,3-oxazolidines, pyrazolo[5,1-b]1,3-oxazines and imidazolidino[1,2-d]pyrazoles were synthesized. These compounds were evaluated in vitro for their ability to inhibit cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) in human whole blood (HWB). Several of the compounds were found to be novel and selective COX-2 inhibitors, the most potent and selective being 1-(5-cyclohexyl (2H,3H-pyrazolo[5,1-b]-1,3-oxazolidin-6-yl)-4-(methylsulfonyl)benzene, 7a (IC(5o) for COX-1>100 microM; for COX-2=1.3 microM).
Assuntos
Compostos Bicíclicos Heterocíclicos com Pontes/síntese química , Inibidores de Ciclo-Oxigenase/síntese química , Isoenzimas/antagonistas & inibidores , Pirazóis/síntese química , Compostos Bicíclicos Heterocíclicos com Pontes/química , Compostos Bicíclicos Heterocíclicos com Pontes/farmacologia , Ciclo-Oxigenase 1 , Ciclo-Oxigenase 2 , Inibidores de Ciclo-Oxigenase 2 , Inibidores de Ciclo-Oxigenase/química , Inibidores de Ciclo-Oxigenase/farmacologia , Humanos , Proteínas de Membrana , Prostaglandina-Endoperóxido Sintases , Pirazóis/química , Pirazóis/farmacologia , Relação Estrutura-AtividadeRESUMO
A novel series of benzo-1,3-dioxolane metharyl derivatives was synthesized and evaluated for cyclooxygenase-2 (COX-2) and cyclooxygenase-1 (COX-1) inhibition in human whole blood (HWB). In the present study, structure-activity relationships (SAR) in the metharyl analogues were investigated. The spacer group and substitutions in the spacer group were found to be quite important for potent COX-2 inhibition. Compounds in which a methylene group (8a-c), carbonyl group (12a-c), or methylidene group (7a-c) connected cycloalkyl groups to the central benzo-1,3-dioxolane template were found to be potent and selective COX-2 inhibitors. Aryl-substituted compounds linked to the central ring by either a methylene or a carbonyl spacer resulted in potent, highly selective COX-2 inhibitors. In this series of substituted-(2H-benzo[3,4-d]1,3-dioxolan-5-yl))-1-(methylsulfonyl)benzene compounds, SAR studies demonstrated that substitution at the 3-position of the aryl group optimized COX-2 selectivity and potency, whereas substitution at the 4-position attenuated COX-2 inhibition. Mono- or difluoro substitution at meta position(s), as in 22c and 22h, was advantageous for both in vitro COX-2 potency and selectivity (e.g., COX-2 IC(50) for 22c = 1 microM and COX-1 IC(50) for 22c = 20 microM in HWB assay). Several novel compounds in the (2H-benzo[3,4-d]1,3-dioxolan-5-yl))-1-(methylsulfonyl)benzene series, as shown in structures 7c, 8a, 12a, 21c, 22c, 22e, and 22h, selectively inhibited COX-2 activity by 40-50% at a test concentration of 1 microM in an in vitro HWB assay.
Assuntos
Inibidores de Ciclo-Oxigenase/síntese química , Cicloparafinas/síntese química , Dioxolanos/síntese química , Isoenzimas/antagonistas & inibidores , Doença Aguda , Administração Oral , Animais , Ciclo-Oxigenase 2 , Inibidores de Ciclo-Oxigenase 2 , Inibidores de Ciclo-Oxigenase/química , Inibidores de Ciclo-Oxigenase/farmacologia , Cicloparafinas/química , Cicloparafinas/farmacologia , Dioxolanos/química , Dioxolanos/farmacologia , Feminino , Humanos , Técnicas In Vitro , Inflamação/tratamento farmacológico , Masculino , Proteínas de Membrana , Prostaglandina-Endoperóxido Sintases , Ratos , Relação Estrutura-AtividadeRESUMO
Despite its widespread use, diclofenac has gastrointestinal liabilities common to nonsteroidal antiinflammatory drugs (NSAIDs) that might be reduced by concomitant administration of a gastrointestinal cytoprotectant such as nitric oxide (NO). A series of novel diclofenac esters containing a nitrosothiol (-S-NO) moiety as a NO donor functionality has been synthesized and evaluated in vivo for bioavailability, pharmacological activity, and gastric irritation. All S-NO-diclofenac derivatives acted as orally bioavailable prodrugs, producing significant levels of diclofenac in plasma within 15 min after oral administration to mice. At equimolar oral doses, S-NO-diclofenac derivatives (20a-21b) displayed rat antiinflammatory and analgesic activities comparable to those of diclofenac in the carrageenan-induced paw edema test and the mouse phenylbenzoquinone-induced writhing test, respectively. All tested S-NO-diclofenac derivatives (20a-21b) were gastric-sparing in that they elicited markedly fewer stomach lesions as compared to the stomach lesions caused by a high equimolar dose of diclofenac in the rat. Nitrosothiol esters of diclofenac comprise a novel class of NO-donating compounds having therapeutic potential as nonsteroidal antiinflammatory agents with an enhanced gastric safety profile.
Assuntos
Anti-Inflamatórios não Esteroides/síntese química , Diclofenaco/síntese química , Compostos Nitrosos/síntese química , Pró-Fármacos/síntese química , Animais , Anti-Inflamatórios não Esteroides/química , Anti-Inflamatórios não Esteroides/farmacocinética , Anti-Inflamatórios não Esteroides/farmacologia , Disponibilidade Biológica , Diclofenaco/química , Diclofenaco/farmacocinética , Diclofenaco/farmacologia , Masculino , Camundongos , Compostos Nitrosos/química , Compostos Nitrosos/farmacocinética , Compostos Nitrosos/farmacologia , Pró-Fármacos/química , Pró-Fármacos/farmacocinética , Pró-Fármacos/farmacologia , Ratos , Ratos Sprague-Dawley , Estômago/patologia , Relação Estrutura-AtividadeRESUMO
Occupational therapy focuses on complex dynamic relationships between people, occupations and environments. Therapists must clearly communicate their practices and how their practice influences outcomes. This paper explores applications of the Person-Environment-Occupation Model (Law et al., 1996) in occupational therapy practice, and delineates how this particular model helps therapists to conceptualize, plan, communicate and evaluate occupational performance interventions. Three case studies illustrate how the model can be used by occupational therapists to systematically approach analysis of occupational performance issues while considering the complexities of human functioning and experience. The ways in which the model facilitates communication within and outside occupational therapy are explained. The Person-Environment-Occupation Model is offered as a tool for therapists to use in client(s)-therapist alliances to enable clients to successfully engage in meaningful occupations in chosen environments.
Assuntos
Modelos Psicológicos , Terapia Ocupacional , Idoso , Idoso de 80 Anos ou mais , Criança , Feminino , Humanos , Masculino , Relações Profissional-PacienteRESUMO
We designed and evaluated a new class of molecules, nitrosylated alpha-adrenergic receptor antagonists, as potential agents for the treatment of impotence. In in vitro studies with human and rabbit corpus cavernosum strips in organ chambers, the alpha-adrenergic receptor antagonists (alpha-ARAs) moxisylyte and yohimbine and their corresponding nitrosylated compounds, SNO-moxisylyte (NMI-221) and SNO-yohimbine (NMI-187), concentration-dependently relaxed endothelin-induced contraction. The nitrosylated compounds were significantly more potent than the parent alpha-ARA. In human tissues, the specific phosphodiesterase type 5 inhibitor zaprinast potentiated the relaxing effects of the nitrosylated compounds. Only nitrosylated compounds induced accumulation of cyclic GMP in rabbit corpus cavernosum strips. Yohimbine and NMI-187 demonstrated a potent alpha2-blocking activity, with no significant differences in pA2 values (8.9 versus 8.2, respectively). Moxisylyte and NMI-221 showed moderate potency in antagonizing phenylephrine contraction, with comparable pA2 values for both molecules (6.5 versus 6.6, respectively). alpha-Adrenergic receptor-binding studies showed similar binding affinities for the alpha-ARA and their corresponding nitrosylated compounds. In vivo, intracavernosal injection of nitrosylated molecules caused greater increases in intracavernosal pressure (NMI-221 versus moxisylyte) that were more long lasting than those of moxisylyte or yohimbine. There were no significant differences between nitrosylated and non-nitrosylated compounds in the magnitude of systemic mean arterial pressure decrease after intracavernosal injection. alpha-ARA and the nitrosylated compounds showed no pain-inducing activity as evaluated with the paw-lick model in mice. In summary, nitrosylated alpha-ARA have the dual functionalities of nitric oxide donors and alpha-ARA. These drugs induced penile erection in animals, suggesting their possible therapeutic value as agents for the local pharmacological treatment of impotence.
Assuntos
Antagonistas Adrenérgicos alfa/síntese química , Disfunção Erétil/tratamento farmacológico , Moxisilita/análogos & derivados , Compostos Nitrosos/síntese química , Compostos Nitrosos/farmacologia , Vasodilatadores/síntese química , Ioimbina/análogos & derivados , Antagonistas Adrenérgicos alfa/metabolismo , Antagonistas Adrenérgicos alfa/farmacologia , Animais , GMP Cíclico/metabolismo , Desenho de Fármacos , Endotelinas/farmacologia , Humanos , Técnicas In Vitro , Masculino , Membranas , Camundongos , Moxisilita/síntese química , Moxisilita/metabolismo , Moxisilita/farmacologia , Contração Muscular/efeitos dos fármacos , Músculo Liso Vascular/efeitos dos fármacos , Pênis/efeitos dos fármacos , Pênis/metabolismo , Pênis/fisiologia , Fenilefrina/farmacologia , Coelhos , Ratos , Ratos Sprague-Dawley , Receptores Adrenérgicos alfa 1/efeitos dos fármacos , Receptores Adrenérgicos alfa 1/metabolismo , Vasodilatadores/metabolismo , Vasodilatadores/farmacologia , Ioimbina/síntese química , Ioimbina/metabolismo , Ioimbina/farmacologiaRESUMO
Programme evaluation has become an important component of many rehabilitation initiatives in both institutional and community environments. Of key importance is a need for information on developing an evaluation framework to determine and address programme processes and outcomes. This paper presents a programme logic model used to guide the evaluation of a community rehabilitation programme for adults with brain injury. Programme logic models are visual models that provide a framework to organize and integrate information about programme inputs, processes and outcomes. The model is also used in this programme to incorporate the client-centred values of the programme. It was developed through the consensus of the entire team, and was used to plan implementation and outcome evaluations. A similar programme logic model will be useful to occupational therapists and other health care professionals planning programme evaluations of their services.
Assuntos
Lesões Encefálicas/reabilitação , Serviços de Saúde Comunitária/normas , Modelos Organizacionais , Terapia Ocupacional/normas , Avaliação de Programas e Projetos de Saúde/métodos , Adulto , Canadá , Centros Comunitários de Saúde/organização & administração , Centros Comunitários de Saúde/normas , Serviços de Saúde Comunitária/organização & administração , Humanos , Ontário , Avaliação de Processos e Resultados em Cuidados de Saúde , Assistência Centrada no Paciente/organização & administração , Assistência Centrada no Paciente/normas , Centros de Reabilitação/organização & administração , Centros de Reabilitação/normasRESUMO
Occupational therapists have begun to recognize the importance of considering how the environment influences occupational performance. Models of person-environment fit provide a theoretical context within which occupational therapists can consider the influence of the environment on function. The challenge for occupational therapists is to select assessments that incorporate concepts of person-environment fit. However, limited awareness of appropriate environmental assessments that have undergone psychometric testing has limited their introduction into clinical practice. This paper reviews 41 environmental assessments and considers each in terms of its purpose, environmental attribute, environmental application, clinical utility, instrument development, and psychometric testing. A case example illustrates the applicability to the practice of occupational therapy.
Assuntos
Atividades Cotidianas , Meio Ambiente , Modelos Teóricos , Terapia Ocupacional/métodos , Estudos de Avaliação como Assunto , Humanos , Psicometria , Reprodutibilidade dos TestesRESUMO
The interaction that occurs between individuals and their environment is central to all work and rehabilitation practice. In the past, rehabilitation has focused more on facilitating personal adaptation and less on understanding the influence of the environment on behavior. Eight person-environment models, developed by other disciplines but of relevance to rehabilitation, are presented and discussed. The way in which each of these models views the person, the environment, the person-environment relationship, and adaptation is compared and contrasted to views inherent in rehabilitation practice. The literature suggests that rehabilitation is gradually moving from an interactive perspective of person-environment fit toward a transaction view that more accurately acknowledges the complexity and the entwined nature of these issues.